Monday, February 16, 2026 2/16/2026

Oncology Knowledge Rapid Alerts: Integrating biomarker-driven clinical decision support for therapy selection at point-of-care

Award Number: R21CA274545
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/19/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

Oncology Knowledge Rapid Alerts: Integrating biomarker-driven clinical decision support for therapy selection at point-of-care - PROJECT SUMMARY/ABSTRACT Precision cancer medicine uses patient molecular test results to guide cancer therapy selection. An increasing number of cancer therapies are now targeted to specific molecular alterations, and tumor molecular testing is now standard of care. A significant obstacle in advancing precision cancer therapy is the rapid pace of change in this field—making it challenging for oncologists to stay up to date. The long-term goal of this project is to integrate clinical decision support (CDS) for precision cancer therapy selection directly into the electronic health record (EHR). Ultimately, we will create an integrated CDS solution within the EHR that includes best practice alerts to oncologists and integration of CDS into the molecular testing result report. The objective of this R21 is to develop a CDS algorithm to match molecular test results to targeted therapy assertions from a widely used precision oncology knowledgebase, deliver an open-source web service application programming interface (API) that can support vendor-agnostic integration with any EHR that uses the new genomic data standards, and provide proof-of-concept, point-of-care CDS in our local EHR environment. We will accomplish this through the following specific aims: Aim 1. Develop an open-source algorithm and API for computing and storing biomarker-driven CDS from the My Cancer Genome (MCG) knowledgebase. We will develop an algorithm that will compute targeted therapy options for a patient’s tumor histology and molecular profile from the data stored in the MCG knowledgebase. We will build a web service API that receives molecular testing data, calls the MCG knowledgebase, runs the CDS algorithm, and outputs the computed CDS in a format that can be stored for rapid retrieval and that is compatible with EHRs using the new genomic data standards. Aim 2. Develop methods for integration of biomarker-driven CDS into the EHR as human-readable statements. In this aim, we will build API functions to receive communications from the EHR when an oncologist views tumor test results, retrieve cached CDS, and send CDS to the EHR. Using non-small cell lung cancer as a proof-of-concept, our initial use cases will provide integration of CDS with the molecular results report and best practice alerts to oncologists. This project will provide tools to match patient molecular test results to appropriate targeted therapies. At the conclusion of this project, an oncologist will be able to view CDS when they access patient molecular results in the EHR. This point-of-care CDS will facilitate delivery of the right information to the right person at the right time to maximize impact on clinical care.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$867 )
2026	2022	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Detection and Diagnosis Research	000	1	12/12/2025	NEW	-$867
														Subtotal = -$867

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Detection and Diagnosis Research	000	1	10/15/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $449,971 )
2022	2022	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Detection and Diagnosis Research	000	1	9/19/2022	NEW	$449,971
														Subtotal = $449,971

Grand Total All Awards = $449,104

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Oncology Knowledge Rapid Alerts: Integrating biomarker-driven clinical decision support for therapy selection at point-of-care

Award Number: R21CA274545

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/19/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer